Chaturbedi Abhishek, Yu Liping, Linskey Mark E, Zhou Yi-Hong
Department of Neurological Surgery, University of California, Irvine, CA.
Biomark Insights. 2012;7:9-17. doi: 10.4137/BMI.S9003. Epub 2012 Feb 1.
1p/19q (1p and/or 19q) deletions are prognostic factors in oligodendroglial tumors (OT) and predict better survival after both chemotherapy and radiotherapy. While studying 1p/19q status as a potential variable within multivariate prognosis models for OT, we have frequently encountered unknown 1p/19q status within our glioma sample database due to lack of paired blood samples for loss of heterozygosity (LOH) assay and/or failure to perform fluorescence in situ hybridization (FISH). We realized that a 1p and 19q deletion assay that could be reliably performed solely on tumor DNA samples would allow us to fill in these molecular biology data "holes". We built recombinant DNA with fragments of the selected "marker" genes in 1p (E2F2, NOTCH2), and 19q (PLAUR) and "reference" genes (ERC2, SPOCK1, and SPAG16 ) and used it as quantification standard in real-time PCR to gain absolute ratios of marker/reference gene copy numbers in tumor DNA samples, thus called comparative quantitative PCR (CQ-PCR). Using CQ-PCR, we identified 1p and/ or 19q deletions in majority of pure low-grade oligodenroglioma (OG) tumors (17/21, 81%), a large portion of anaplastic oligodendroglioma (AO) tumors (6/15, 47%), but rarely found in mixed oligoastrcytomas (OA) tumors (1/8, 13%). These data are consistent with results of LOH and FISH assays generally reported for these tumor types. In addition, 15 out 18 samples showed concordant results between FISH and CQ-PCR. We conclude that CQ-PCR is a potential means to gain 1p/19q deletion information, which prognostic and predictive values of CQ-PCR-derived 1p/19q status will be determined in a future study.
1p/19q(1p和/或19q)缺失是少突胶质细胞瘤(OT)的预后因素,且预示着化疗和放疗后有更好的生存率。在研究将1p/19q状态作为OT多因素预后模型中的一个潜在变量时,由于缺乏用于杂合性缺失(LOH)检测的配对血液样本和/或未能进行荧光原位杂交(FISH),我们在胶质瘤样本数据库中经常遇到1p/19q状态未知的情况。我们意识到,一种仅能在肿瘤DNA样本上可靠进行的1p和19q缺失检测方法将使我们能够填补这些分子生物学数据的“空白”。我们用1p(E2F2、NOTCH2)和19q(PLAUR)中选定的“标记”基因片段以及“参考”基因(ERC2、SPOCK1和SPAG16)构建重组DNA,并将其用作实时PCR中的定量标准,以获取肿瘤DNA样本中标记/参考基因拷贝数的绝对比值,因此称为比较定量PCR(CQ-PCR)。使用CQ-PCR,我们在大多数纯低级别少突胶质细胞瘤(OG)肿瘤(17/21,81%)、很大一部分间变性少突胶质细胞瘤(AO)肿瘤(6/15,47%)中检测到1p和/或19q缺失,但在混合性少突星形细胞瘤(OA)肿瘤中很少发现(1/8,13%)。这些数据与这些肿瘤类型通常报道的LOH和FISH检测结果一致。此外,18个样本中有15个在FISH和CQ-PCR之间显示出一致的结果。我们得出结论,CQ-PCR是获取1p/19q缺失信息的一种潜在方法,CQ-PCR衍生的1p/19q状态的预后和预测价值将在未来的研究中确定。